Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 2/20 | 0.42 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8100060 | 0.86 | CACNA2D1 (0.44) | ALDH1A1MEN1KMT2ATDP1SLC2A1 | |
| SCHEMBL13944418 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ATDP1CASR | |
| SCHEMBL6689198 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ATDP1CASR | |
| SCHEMBL10780978 | 0.80 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ATDP1CASR | |
| SCHEMBL11400305 | 0.80 | POLB (0.53) | ALDH1A1MEN1KMT2AGAAPOLB | |
| SCHEMBL9709298 | 0.79 | MEN1 (0.65) | ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL21730504 | 0.78 | MAPT (0.46) | ALDH1A1MEN1KMT2ATDP1GAA | |
| SCHEMBL8908084 | 0.77 | KMT2A (0.79) | ALDH1A1MEN1KMT2ATDP1GAA | |
| SCHEMBL29183283 | 0.77 | ALDH1A1 (0.55) | ALDH1A1POLBPKM | |
| SCHEMBL11697544 | 0.77 | MEN1 (0.50) | ALDH1A1MEN1KMT2ATDP1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150073165-A1 | CATALYST COMPOUNDS | THE UNIVIERSITY OF LIVERPOOL (GB) | 2015-03-12 | — | — | US | disclosed |
| US-20150073165-A1 | CATALYST COMPOUNDS | THE UNIVIERSITY OF LIVERPOOL (GB) | 2015-03-12 | — | — | US | disclosed |
| WO-2013153408-A1 | CATALYST COMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2013-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073165-A1 | CATALYST COMPOUNDS | NQO1, IDH2, IDH3B | ALDH1A1 115/4885MEN1 262/4885KMT2A 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.